Saturday 17 October 2026
Export PDLI’s income statement to Excel — free account
PDL BioPharma, Inc.
Follow PDLI
PDL BioPharma, Inc. (PDLI) EV/Sales
As of 6 January 2021, PDL BioPharma, Inc. (PDLI) trades at a EV/Sales of 3.8×. Over the past ten years it has ranged from −0.1× (February 2018) to 5.7× (August 2020); the current reading is higher than 89% of that period. That is above the Other industry median of 2.1× and above the Other sector median of 2.1×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2019 | 4.5× | 478.50% |
| FY2018 | 0.8× | 687.82% |
| FY2017 | 0.1× | (93.29%) |
| FY2016 | 1.5× | 46.43% |
| FY2015 | 1.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2020 | 4.2× | 48.49% |
| Mar 2020 | 2.9× | (35.82%) |
| Dec 2019 | 4.5× | 459.88% |
| Sep 2019 | 0.8× | (51.07%) |
| 18 more quarters | Free account |
Against its own ten years
Low −0.1×
High 5.7×
Ten-year median
1.2×
Current reading's percentile
89
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PDLI PDL BioPharma, Inc. | 3.8× |
| Other industry median | 2.1× |
| Other sector median | 2.1× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)